# Nido Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nido-biosciences

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.nidobio.com
- Total disclosed funding: $83M
- Latest round: Series B (May 15, 2023)
- Investors on record: 6

## About

Based in Massachusetts, US, and founded in 2018, Nido Biosciences, Inc. is a biotech company that helps in curing severe neurological diseases and develops medicines that address the fundamental biology of disease and restore healthy cell function. In May 2023, Nido Biosciences, Inc. raised USD 86.6 million in series B funding led by new investor Bioluminescence Ventures, with participation from individuals and other unspecified investors.
 

The company focuses on creating small molecules by utilizing induced pluripotent stem cells derived from patient neural cells. Its treatments can find biological modulators of neurodegenerative diseases, enabling medical practitioners to treat patients and improve their quality of life.

## Funding rounds

- Series B, May 15, 2023, $60M — Bioluminescence Ventures
- Series A, Aug 24, 2020, $18M — Abingworth, 5AM Ventures, OUP (Osage University Partners), Bessemer Venture Partners, Eli Lilly & Company
- Seed, Aug 26, 2019, $4M — 5AM Ventures

## Investors

- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Seed, Series A
- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series A
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series A
- Eli Lilly & Company — Series A
- Bioluminescence Ventures (https://capitalatlas.ai/funds/bioluminescence-ventures) — Series B